Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions

Thomas Hartung, Wolf Dietrich Doecke, Daniela Bundschuh, MaryAnn Foote, Florian Gantner, Corinna Hermann, Andre Lenz, Steven Milwee, Bill Rich, Bernadett Simon, Hans Dieter Volk, Sonja Von Aulock, Albrecht Wendel

Research output: Contribution to journalArticle

Abstract

Twenty-four healthy male volunteers received either placebo or 75, 150, or 300 μg filgrastim (recombinant methionyl human granulocyte colony- stimulating factor) for 12 days to study effects on monocytes and lymphocytes. In all filgrastim-treated groups, tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and interferon gamma (IFN-γ) release by whole blood in response to endotoxin (lipopolysaccharide) was reduced. IL-12 added in vitro to lipopolysaccharide-stimulated blood of filgrastim-treated donors restored IFN-γ and TNF-α release, suggesting that the anti- inflammatory effect of granulocyte colony-stimulating factor is exercised through IL-12 suppression. Phytohemagglutinin- or anti-CD3 antibody-induced lymphocyte proliferation ex vivo was reduced by 60% from day 5 to day 15, after a 50% increase at day 2 with concomitant doubled IL-2 release. In vivo, filgrastim induced doubling of all T-cell populations by day 8. Filgrastim decreased proinflammatory cytokine production and lymphocyte proliferation ex vivo throughout prolonged treatment at all doses. This indicates that endogenous granulocyte colony-stimulating factor may counterregulate the inflammatory cytokine cascade and implies a potential indication for filgrastim in chronic inflammatory conditions.

Original languageEnglish (US)
Pages (from-to)415-424
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume66
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Lymphocytes
Cytokines
Interleukin-12
Granulocyte Colony-Stimulating Factor
Therapeutics
Lipopolysaccharides
Tumor Necrosis Factor-alpha
Phytohemagglutinins
Filgrastim
Endotoxins
Interferon-gamma
Interleukin-2
Monocytes
Anti-Idiotypic Antibodies
Healthy Volunteers
Anti-Inflammatory Agents
Placebos
Tissue Donors
T-Lymphocytes
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. / Hartung, Thomas; Doecke, Wolf Dietrich; Bundschuh, Daniela; Foote, MaryAnn; Gantner, Florian; Hermann, Corinna; Lenz, Andre; Milwee, Steven; Rich, Bill; Simon, Bernadett; Volk, Hans Dieter; Von Aulock, Sonja; Wendel, Albrecht.

In: Clinical Pharmacology and Therapeutics, Vol. 66, No. 4, 1999, p. 415-424.

Research output: Contribution to journalArticle

Hartung, T, Doecke, WD, Bundschuh, D, Foote, M, Gantner, F, Hermann, C, Lenz, A, Milwee, S, Rich, B, Simon, B, Volk, HD, Von Aulock, S & Wendel, A 1999, 'Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions', Clinical Pharmacology and Therapeutics, vol. 66, no. 4, pp. 415-424. https://doi.org/10.1053/cp.1999.v66.a101210
Hartung, Thomas ; Doecke, Wolf Dietrich ; Bundschuh, Daniela ; Foote, MaryAnn ; Gantner, Florian ; Hermann, Corinna ; Lenz, Andre ; Milwee, Steven ; Rich, Bill ; Simon, Bernadett ; Volk, Hans Dieter ; Von Aulock, Sonja ; Wendel, Albrecht. / Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. In: Clinical Pharmacology and Therapeutics. 1999 ; Vol. 66, No. 4. pp. 415-424.
@article{bbece87f0fa64f47b5a6e37b17a9d201,
title = "Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions",
abstract = "Twenty-four healthy male volunteers received either placebo or 75, 150, or 300 μg filgrastim (recombinant methionyl human granulocyte colony- stimulating factor) for 12 days to study effects on monocytes and lymphocytes. In all filgrastim-treated groups, tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and interferon gamma (IFN-γ) release by whole blood in response to endotoxin (lipopolysaccharide) was reduced. IL-12 added in vitro to lipopolysaccharide-stimulated blood of filgrastim-treated donors restored IFN-γ and TNF-α release, suggesting that the anti- inflammatory effect of granulocyte colony-stimulating factor is exercised through IL-12 suppression. Phytohemagglutinin- or anti-CD3 antibody-induced lymphocyte proliferation ex vivo was reduced by 60{\%} from day 5 to day 15, after a 50{\%} increase at day 2 with concomitant doubled IL-2 release. In vivo, filgrastim induced doubling of all T-cell populations by day 8. Filgrastim decreased proinflammatory cytokine production and lymphocyte proliferation ex vivo throughout prolonged treatment at all doses. This indicates that endogenous granulocyte colony-stimulating factor may counterregulate the inflammatory cytokine cascade and implies a potential indication for filgrastim in chronic inflammatory conditions.",
author = "Thomas Hartung and Doecke, {Wolf Dietrich} and Daniela Bundschuh and MaryAnn Foote and Florian Gantner and Corinna Hermann and Andre Lenz and Steven Milwee and Bill Rich and Bernadett Simon and Volk, {Hans Dieter} and {Von Aulock}, Sonja and Albrecht Wendel",
year = "1999",
doi = "10.1053/cp.1999.v66.a101210",
language = "English (US)",
volume = "66",
pages = "415--424",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions

AU - Hartung, Thomas

AU - Doecke, Wolf Dietrich

AU - Bundschuh, Daniela

AU - Foote, MaryAnn

AU - Gantner, Florian

AU - Hermann, Corinna

AU - Lenz, Andre

AU - Milwee, Steven

AU - Rich, Bill

AU - Simon, Bernadett

AU - Volk, Hans Dieter

AU - Von Aulock, Sonja

AU - Wendel, Albrecht

PY - 1999

Y1 - 1999

N2 - Twenty-four healthy male volunteers received either placebo or 75, 150, or 300 μg filgrastim (recombinant methionyl human granulocyte colony- stimulating factor) for 12 days to study effects on monocytes and lymphocytes. In all filgrastim-treated groups, tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and interferon gamma (IFN-γ) release by whole blood in response to endotoxin (lipopolysaccharide) was reduced. IL-12 added in vitro to lipopolysaccharide-stimulated blood of filgrastim-treated donors restored IFN-γ and TNF-α release, suggesting that the anti- inflammatory effect of granulocyte colony-stimulating factor is exercised through IL-12 suppression. Phytohemagglutinin- or anti-CD3 antibody-induced lymphocyte proliferation ex vivo was reduced by 60% from day 5 to day 15, after a 50% increase at day 2 with concomitant doubled IL-2 release. In vivo, filgrastim induced doubling of all T-cell populations by day 8. Filgrastim decreased proinflammatory cytokine production and lymphocyte proliferation ex vivo throughout prolonged treatment at all doses. This indicates that endogenous granulocyte colony-stimulating factor may counterregulate the inflammatory cytokine cascade and implies a potential indication for filgrastim in chronic inflammatory conditions.

AB - Twenty-four healthy male volunteers received either placebo or 75, 150, or 300 μg filgrastim (recombinant methionyl human granulocyte colony- stimulating factor) for 12 days to study effects on monocytes and lymphocytes. In all filgrastim-treated groups, tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and interferon gamma (IFN-γ) release by whole blood in response to endotoxin (lipopolysaccharide) was reduced. IL-12 added in vitro to lipopolysaccharide-stimulated blood of filgrastim-treated donors restored IFN-γ and TNF-α release, suggesting that the anti- inflammatory effect of granulocyte colony-stimulating factor is exercised through IL-12 suppression. Phytohemagglutinin- or anti-CD3 antibody-induced lymphocyte proliferation ex vivo was reduced by 60% from day 5 to day 15, after a 50% increase at day 2 with concomitant doubled IL-2 release. In vivo, filgrastim induced doubling of all T-cell populations by day 8. Filgrastim decreased proinflammatory cytokine production and lymphocyte proliferation ex vivo throughout prolonged treatment at all doses. This indicates that endogenous granulocyte colony-stimulating factor may counterregulate the inflammatory cytokine cascade and implies a potential indication for filgrastim in chronic inflammatory conditions.

UR - http://www.scopus.com/inward/record.url?scp=0032717657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032717657&partnerID=8YFLogxK

U2 - 10.1053/cp.1999.v66.a101210

DO - 10.1053/cp.1999.v66.a101210

M3 - Article

C2 - 10546926

AN - SCOPUS:0032717657

VL - 66

SP - 415

EP - 424

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -